Foundation1999 - 2002

June 1999

Founded Kolon TissueGene

June 2000

License Agreement with Kolon Life Science

October 2001

Secured US Patent with INVOSSA™ Related Technology (Gene Therapy Utilizing TGF-β1)

Early Phase Clinical TrialsGrowth 2003 - 2012

September 2004

Obtained US patent related to INVOSSA(USP 6,797,703) "Gene therapy using TGF-β1"

August 2005

Selected as a National Project by Korean Ministry of Trade, Industry and Energy

December 2006

Clearance for US Phase I Clinical Trial

April 2009

Completed Administration of Patients for US Phase I

November 2010

Clearance for US Phase II Clinical Trial

October 2012

Completed Administration of Patients for US Phase II

US Clinical Trials & CommercializationRapid Progress 2013~

May 2015

Clearance for US Phase III Clinical Trial (SPA)

November 2015

Appointed as a Global Innovative Biotherapeutics Technology Development Research Center

May 2016

Equity Investment of K-EXIM Bank

November 2016

Sublicense Agreement between Kolon Life Science and Japanese Mitsubishi Tanabe

April 2017

Secured AA Grade from Technology Assessment by NICE

November 2017

Listed on KOSDAQ stock market in Korea

March 2018

Changed company name, Kolon TissueGene, Inc.